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Aim To assess the quality of real-life warfarin anticoagula-
tion in patients requiring chronic thromboprophylaxis in a 
southern Croatian county.
Methods We retrospectively analyzed international nor-
malized ratio (INR) values determined over one year (2016-
2017) at the Zadar County General Hospital in warfarin-
treated patients requiring chronic thromboprophylaxis. The 
values represent 83.0% of all INRs and were determined in 
84.0% of all warfarin-treated patients in the county during 
the observed period.
Results Overall 31 162 INRs were taken from 3697 patients, 
2240 of whom (20 851 INRs, 3-56 per patient, median 9) 
were referred with diagnoses requiring chronic throm-
boprophylaxis: mainly atrial fibrillation/flutter (n = 1508, 
14 902 INRs) but also cardiac implants, valvular disease, 
severe heart failure, and cerebrovascular disease (“other”, 
n = 732, 5949 INRs). Only 50.1% of all INRs were within the 
target range, 2.0-3.5, while 43.6% were <2.0, and 6.3% were 
>3.5. Median crude individual proportion of INRs with-
in the range was 50.0%, while it was 42.0% for INRs <2.0. 
Only 23.0% of the patients had ≥70% of the INRs within 
the target range (adequately anticoagulated), while 35.5% 
had ≤33.3% of the INRs within the range. Conversely, 66.5% 
of the patients had ≥33.3% INRs <2.0. Adjusted probabil-
ity of adequate anticoagulation in atrial fibrillation/flutter 
patients was consistently 25.5% to 27.7%, regardless of the 
number of determined INRs, while in patients with other 
conditions it increased from 9.5% to 25.2% with a higher 
number of INRs.
Conclusion The achieved level of warfarin anticoagula-
tion in this real-life setting is far below what is needed for 
effective long-term thromboprophylaxis.
Received: December 7, 2018
Accepted: February 11, 2019
Correspondence to: 
Vladimir Trkulja 
Department of Pharmacology 
Zagreb University School of 
Medicine 
Šalata 11 
10000 Zagreb, Croatia 
vtrkulja@mef.hr
Aleksandar Knežević1,2, 
Marijana Nadinić2, Irena 
Užović Frakin2, Vladimir 
Trkulja3
1Department of Health Studies, 
Zadar University, Zadar, Croatia
2County General Hospital Zadar, 
Zadar, Croatia
3Department of Pharmacology, 
University of Zagreb School of 
Medicine, Zagreb, Croatia
Poor warfarin anticoagulation in 
long-term thromboprophylaxis: 
a survey in a southern Croatian 
county
CLINICAL SCIENCE 
 
Croat Med J. 2019;60:2-11 
https://doi.org/10.3325/cmj.2019.60.2
3Knežević et al: Poor warfarin anticoagulation in long-term thromboprophylaxis in Croatia
www.cmj.hr
European and American cardiological and neurological so-
cieties recommend long-term (life-long) anticoagulation 
with classical oral anticoagulants (OACs) – vitamin K an-
tagonists (VKAs) – for primary and secondary prevention of 
stroke/systemic thromboembolism in patients with atrial fi-
brillation/flutter (AF), rheumatic or non-rheumatic valvular 
disease, mechanical artificial valves, chronic heart failure and 
very low ejection fraction (in sinus rhythm), and/or left ven-
tricular thrombi (1-5). Of a number of VKAs that have been 
introduced into medical practice, the most frequently used 
worldwide is warfarin. Over the past 10 years, a new gen-
eration of orally active anticoagulants has been introduced 
– new or non-VKA oral anticoagulants (NOACs) – with prov-
en efficacy and safety in primary thromboprophylaxis in 
patients with non-valvular AF, however warfarin (VKAs) re-
mains the treatment of choice in a number of other settings 
(1-5). In clinical trials, most of which were conducted in non-
valvular AF (the most prevalent condition with increased 
thromboembolic risk), warfarin reduced the risk of stroke/
systemic embolism by around 66% and all-cause mortal-
ity by around 25%, without an increase in the risk of major 
bleedings (1,2). To achieve this balance between the clinical 
risks and benefits, anticoagulant activity of warfarin, illus-
trated by the international normalized ratio (INR), should be 
kept within the range of INR 2.0-3.0, or somewhat higher in 
patients with mechanical prosthetic valves (depending on 
their thrombogenic potential) (2,3). Considering the inher-
ently high inter- and intra-individual variability of warfarin 
anticoagulant activity, partly influenced by genetic deter-
minants but largely by numerous clinically relevant interac-
tions between warfarin and other drugs, foods, and food 
supplements (2,3,6,7), achieving this goal requires constant 
frequent monitoring of prothrombin time (INR), particularly 
at the start of treatment and in patients showing variable 
INRs (2,3). Guidelines recommend that a patient should 
spend ≥70% of time with INR within the target range (time 
in therapeutic range, TTR), as assessed by a method based 
on linear interpolation of INR values (2,3). This goal is achiev-
able in daily practice (8-10), but this refers to health care 
systems that incorporate one or more of the measures like 
wide accessibility of specialized anticoagulation clinics, ap-
plication of point-of-care devices for determination of pro-
thrombin time at home, use of computer algorithms for 
dose adjustments, constant determination of TTR, alerting 
systems for regular INR measurements, and patient regis-
tries. However, this goal is commonly not achieved, even in 
contemporary clinical trials (1,2), and particularly not in dai-
ly practice even in developed countries and well-organized 
health care systems (11,12). TTR, as well as an alternative 
measure of adequacy of warfarin anticoagulation, the per-
centage of determined INR values within the target range 
(12), well predict the success or failure of warfarin thrombo-
prophylaxis: lower values (ie, INR<2.0) predict the increased 
incidence of thromboembolic events, and predominantly 
too high or highly variable values predict the incidence of 
major bleedings (12).
In Croatia, there are no widely accessible coagulation clin-
ics (for the outpatients), no national, regional or institu-
tional patient registries, and the Croatian Health Insurance 
Fund does not reimburse the use of portable coagulom-
eters. The management of long-term warfarin anticoagu-
lation has been formally assigned to general practitioners 
(GPs), however the compliance with the regular INR con-
trols and warfarin dose-adjustments are time-consuming 
and may be difficult to achieve for the outpatients, partic-
ularly those with restricted mobility. Previous reports from 
other settings suggested that warfarin anticoagulation in 
Croatia was poor (13,14), but to our knowledge there have 
been no reports providing a deeper insight into the ad-
equacy of warfarin treatment specifically in patients who 
require long-term anticoagulation. We aimed to assess the 
adequacy of warfarin anticoagulation in patients requiring 
long-term thromboprophylaxis in the Zadar County, Croa-
tia, over a one-year period.
PATIeNTs ANd MeThods
study area and population
Zadar County is a county in the south of Croatia, encom-
passing a coastal part and several sparsely inhabited is-
lands over a total of 3646 km2 (6.4% of Croatian territory). 
According to the 2011 census (15), the County population 
is 170 000 (4.1% of Croatian population), 124 400 of whom 
are older than 19 years (15). They are served by 99 general 
practices and three hospitals: County General Hospital Za-
dar (in the city of Zadar, the County center), Special Hospi-
tal for Psychiatric Disorders (on the island of Ugljan), and 
Special Hospital for Orthopedic Surgery (in the town of Bi-
ograd) (16). Prothrombin time is determined at the Central 
Laboratory of the County General Hospital (blood samples 
can be taken at the Laboratory or at general practices) and 
at four additional smaller laboratories within a perimeter 
of 25-60 km.
design and ethics
The present study is a retrospective analysis of INR val-
ues determined at the Central Laboratory of the 
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FIgUre 1. (A) Patient disposition. (B) distribution of patients by the number of determined international normalized ratio values 
(INrs) – overall (upper row), by indication (middle row), and by referral mode (bottom row). gP – general practitioner.
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County General Hospital over a one-year period between 
September 1, 2016 and August 31, 2017. It was approved 
by the institutional Ethics Committee (approval No. 02-
6432/18-9/18). During this period, 37 711 INR values in 
4377 warfarin-treated patients were determined cumula-
tively at the five locations in the county. Of those, 31 162 
INRs (83%) in 3697 patients (84%) were determined at the 
County Hospital Central Laboratory. Therefore, the pres-
ent analysis can be considered a screen of the total county 
population. Electronic database at the Central Laboratory 
was searched to anonymously identify all warfarin-treated 
patients referred for prothrombin time and INR determina-
tion. The present study included patients in whom referral 
International Classification of Disease (ICD) codes indicat-
ed that they were under warfarin treatment due to condi-
tions requiring long-term thromboprophylaxis: AF (codes 
I48, I49), chronic heart failure with low ejection fraction/
atrial thrombi (codes I50, I42, also I25), rheumatic or non-
rheumatic valve disease (codes I05, I06, I08, I08, I34, I35, I36, 
I37), history of ischemic stroke or transitory ischemic attack 
(TIA) (codes I63, I64, I74) (addressed as “advanced cerebro-
vascular disease”), or because they had prosthetic valves/
cardiac implants (codes Z95, Z96).
outcomes
For each patient, we determined the proportion of INR 
values that were within the target (therapeutic) INR range 
(2.0-3.5), below it (<2.0), or above it (>3.5). In most condi-
tions requiring long-term thromboprophylaxis, of which 
non-valvular AF is by far predominant, the recommended 
target INR range is 2.0-3.0 (with 2.5 being the “point-tar-
get”) (1-5). We defined the target range as 2.0-3.5 since: a) 
in some conditions, eg, in patients with prosthetic valves, 
the recommended INR target is somewhat higher than INR 
2.0-3.0, depending on thrombogenic potential of the im-
planted valves (2,3). Only a minor portion of patients fell 
into this category and we assumed that most likely they 
had mechanical prostheses with low thrombogenic po-
tential, hence the targeted INRs would be within the de-
fined range; b) in stably treated patients occasional values 
>3.0 are often tolerated without a prompt dose adjust-
ment as they could be caused by transient interfering fac-
tors (eg, consumption of certain foods, short-term use of 
non-steroidal anti-inflammatory drugs), and a meaningful 
increase in the bleeding risk should be expected with INRs 
>3.5 (2). We defined the “proportion of patients with ≥70% 
of INR values within the target range” as the primary out-
come. The proportion of INRs within the target range cor-
relates well with TTR, hence ≥70% INRs within the range 
corresponds fairly well to TTR≥70%, which illustrates ade-
quate warfarin-based anticoagulation (12).
statistical analysis
Proportion of patients with ≥70% INRs within the target 
range (adequately anticoagulated) is reported overall and 
across patient subsets by referral mode (GPs or internal 
hospital referrals), main diagnosis (AF or “other condi-
tions” cumulatively, since patient numbers by individual 
conditions were limited), and the number of INRs deter-
mined. To evaluate the effects of age, sex, main diagno-
sis, referral mode, and the number of INRs determined, a 
modified Poisson regression model with sandwich error 
estimation was fitted to the proportion of adequately an-
ticoagulated patients. We report adjusted probabilities of 
adequate anticoagulation and relative risks expressed as 
prevalence ratios (PR, since we recorded prevalence, not 
incidence). The number of INRs determined was treated 
as a continuous variable, and was ln-transformed and 
geometric-mean centered since interaction terms be-
tween indication or referral mode and the number of INRs 
were included in the model if P < 0.1. The effect of increas-
ing the number of determined INRs is expressed as PR by 
2-fold increase in the number of INRs. All estimates are 
given with 95% confidence intervals. For illustrative pur-
poses, patients were also classified as those with 3-7, 8-12, 
and >12 INRs determined over the observed year, and 
we additionally report the distribution of patients in re-
spect to the percentage of individual INRs within, below, 
or above the target range. We used SAS for Windows 9.4 
software (SAS Inc., Cary, NC, USA).
resUlTs
The present analysis included 2240 patients with referral 
ICD codes suggesting an indication for long-term (life-
long) thromboprophylaxis (Figure 1A): AF by far prevailed 
over other conditions – valvular disease, chronic heart fail-
ure with an indication for long-term thromboprohylaxis, 
cardiac implants, or a history of stroke or TIA (“advanced 
cerebrovascular disease”). Patients were predominantly 
referred by GPs (Figure 1A). Between 3 and 56 INRs were 
determined per patient (median 9), for 20 851 INRs (Figure 
1A). More INRs per patient were determined in AF patients 
than in patients with other conditions, and in GP-referred 
patients than in internal hospital referrals (Figure 1B).
Only 50.1% of all INRs were within the target range, 
with a high proportion of INRs <2.0 and with only 
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sporadic values >3.5 (Figure 2A). Crude proportions of INRs 
within the target range varied between 0 and 100% in in-
dividual patients (Figure 2B), and the median overall pro-
portion was 50.0%. Only 23.0% of patients had ≥70% of 
the values in the target range (adequately anticoagulated), 
while 35.5% had ≤33.3% of the values in the target range 
(Figure 2B). At the same time, the proportions of INRs <2.0 
also varied between 0 and 100%, and the median overall 
proportion was 42.0%, while 66.5% patients had ≥33.3% 
of the values <2.0 (Figure 2B). Therefore, values not in the 
target range were practically exclusively too low. Ade-
quately anticoagulated patients (n = 515, 23.0%) and those 
FIgUre 2. (A) distribution of international normalized ratio values (INrs) below, within, or above the target range. (B) raw individual 
INrs presented as the percentage of determined INrs that were below the target range (INr<2.0), within the target range (INr 
2.0-3.5), and above it (INr>3.5). dots are individual patient data, boxes indicate quartiles, horizontal lines indicate median values 
(depicted also numerically), and bars are inner fences. data outside fences are outliers. horizontal gray bars illustrate patient distri-
bution in respect to percentage of low, target, and high INrs. Upper horizontal dashed line for “INr 2.0-3.5” indicates the cut-off of 
70%: depicted is the number (percentage) of patients with ≥70% of the values within the target range, ie, those who were antico-
agulated in line with the guidelines. lower horizontal dashed line indicates the cut-off of 33.3%: depicted is the number (proportion) 
of patients with ≤33.3% of INrs within the target range, and the number (proportion) of patients with ≥33.3% of INrs that were too 
low or too high.
TAble 1. Patients characteristics, overall and by achieved recommended proportion (≥70%) of international normalized ratio (INr) 
values within the target range. data are count (percent) or median (range)
All ≥70% INrs in range <70% INrs in range
N 2240 515 1725
Men 1209 (54.0) 267 (51.8)  942 (54.6)
Age   77 (21-102)  78 (40-97)   77 (21-102)
referred by
general practitioners 2014 (89.9) 457 (88.7) 1557 (90.3)
internal hospital referral  226 (10.1)  58 (11.3)  168 (9.7)
Main diagnosis
atrial fibrillation/flutter 1508 (67.3) 405 (78.6) 1103 (63.9)
other conditions  732 (32.7) 110 (21.4)  622 (36.1)
Number of INrs determined    9 (3-56)  10 (3-25)    9 (3-56)
3-7  886 (39.6) 144 (28.0)  742 (43.0)
8-12  846 (37.8) 294 (57.1)  552 (32.0)
>12  508 (22.7)  77 (14.9)  431 (25.0)
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who were not (n = 1725) were comparable regarding sex, 
age, and referral mode (Table 1), but in the former group 
there were more patients with AF (Table 1). Also, among 
adequately anticoagulated patients there were more pa-
tients with 8-12 INRs determined and fewer patients with 
3-7 or >12 INRs determined (Table 1). The proportion of 
adequately anticoagulated patients was consistently low 
across all subsets (Figure 3A): in patients with AF (26.9%) 
and in those with other conditions (15.0%); in GP-referred 
(22.7%) and internally referred (25.7%) patients; and in pa-
tients with 3-7 INRs determined (16.3%) and those with 
>12 INRs determined (15.2%), likely reflecting oscillations 
at an earlier treatment stage or in patients with excessive 
variability, although it was somewhat higher in patients 
with 8-12 INRs determined (34.8%) (Figure 3A). At the same 
time, the proportion of patients with ≤33.3% of INRs in the 
FIgUre 3. distribution of patients by subsets based on indication, referral mode, and the number of determined INrs in respect to: 
(A) percentage of international normalized ratio values (INrs) within the target range; (B) percentage of INrs below the target range. 
dots are individual patient data, boxes indicate quartiles, horizontal lines indicate median values (depicted also numerically), and 
bars are inner fences. data outside fences are outliers. horizontal dashed lines in (A) indicate cut-offs of 70% and 33.3% – depicted 
are numbers (proportions) of patients with ≥70% of INrs within the target range (adequately anticoagulated) and numbers (propor-
tions) with ≤33.3% within the range. horizontal dashed line in (B) indicates the cut-off of 33.3% – depicted are numbers (propor-
tions) of patients with ≥33.3% INrs below the target range.
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target range varied from 16.9% to 62.9% (Figure 3A). Me-
dian proportions of values in the target range generally fol-
lowed the pattern of the proportion of adequate anticoag-
ulation (Figure 3A). Individual proportions of INRs <2.0 also 
varied between 0%-100% across the patient subsets, with 
medians mirroring those of proportions in the target range 
TAble 2. Independent effects of diagnosis, referral mode, and the number of determined international normalized ratio (INr)* 
values on the probability of having ≥70% of INrs within the target range (INr 2.0-3.5): summary of multivariate analysis. effects are 
prevalence ratios (Pr) with 95% confidence intervals (CI). Prevalence ratios for the interaction terms indicate whether the effects of 
diagnosis and referral mode differed at different numbers of taken INr values, and vice-versa. Contrasts from the interaction terms 
are without P-values as they serve to illustrate differences in effects at different levels of the involved variables and not to test their 
significance
Pr (95% CI) P
Number of INr values taken (by 2-fold) 1.15 (0.99-1.35)  0.074
Main diagnosis (atrial fibrillation/flutter vs other) 1.67 (1.36-2.04) <0.001
Main diagnosis x number of INrs 0.66 (0.55-0.79) <0.001
atrial fibrillation/flutter vs other - 3 INRs 3.00 (2.11-4.29)  —
atrial fibrillation/flutter vs other - 6 INRs 1.98 (1.58-2.48)  —
atrial fibrillation/flutter vs other - 9 INRs 1.55 (1.27-1.89)  —
atrial fibrillation/flutter vs other - 12 INRs 1.24 (0.99-1.54)  —
atrial fibrillation/flutter vs other - 15 INRs 1.14 (0.90-1.44)  —
number of INRs (by 2-fold) in patients with atrial fibrillation 0.94 (0.80-1.09)  —
number of INRs (by 2-fold) in patients with other conditions 1.42 (1.16-1.75)  —
referred by (general practitioner [gP] vs internal hospital referral) 1.02 (0.76-1.37)  0.913
referred by x number of INrs 0.77 (0.57-1.04)  0.085
referred by GPs vs internal referral - 3 INRs 0.70 (0.48-1.03)  —
referred by GPs vs internal referral - 6 INRs 0.91 (0.70-1.18)  —
referred by GPs vs internal referral - 9 INRs 1.06 (0.77-1.47)  —
referred by GPs vs internal referral - 12 INRs 1.23 (0.79-1.91)  —
referred by GPs vs internal referral - 15 INRs 1.29 (0.79-2.11)  —
number of INRs (by 2-fold) in GPs-referred patients 1.32 (1.20-1.44)  —
number of INRs (by 2-fold) in patients referred internally 1.01 (0.75-1.36)  —
Age (by 10 years) 1.03 (0.95-1.10)  0.434
sex (men vs women) 0.96 (0.82-1.11)  0.568
*The number of determined INrs was ln-transformed and geometric-mean centered. The effect of the number of INrs is given by 
2-fold increase {PR = exp[β x ln(2)]}.
FIgUre 4. Adjusted probabilities (model in Table 2) of having ≥70% of INrs within the target range. (A) Adjusted probabilities (95% 
confidence intervals) from the interaction term between indication and the number of determined INrs. (B) Adjusted probabilities 
(95% confidence intervals) from the interaction term between referral mode and the number of determined INrs. (C) Adjusted prob-
abilities summarized by by-indication-by category of numbers of determined INrs; diamonds are median probabilities (depicted 
numerically) and bars are ranges.
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(Figure 3B). Accordingly, the proportion of patients with 
≥33.3% of values <2.0 was consistently very high (53.9% to 
72.7%) (Figure 3B).
In a multivariate analysis (Table 2), the probability of ad-
equate anticoagulation increased by 15% (95% CI -1 to 
35%), with a 2-fold increase in the number of determined 
INRs. At the average number of INRs, the probability was 
by 67% higher in patients with AF than in those with other 
conditions (Table 2). A significant interaction between in-
dication and the number of determined INRs with PR<1.0 
indicated that the difference between the two subsets 
decreased with increasing number of INRs (Table 2). Con-
versely, in patients with AF, higher number of determined 
INRs was not associated with the probability of adequate 
anticoagulation, whereas in patients with other conditions 
it increased by 42% with a 2-fold increase in the number of 
INRs (Table 2, Figure 4A). Patients referred by GPs and those 
referred internally did not differ in the probability of ad-
equate anticoagulation (Table 2), and the interaction be-
tween referral mode and the number of determined INRs 
suggested that the difference between subsets changed 
with increased number of determined INRs (Table 2). Con-
versely, in GP-referred patients, the probability increased 
by 32% with a 2-fold increase in number of INRs, while no 
such trend was observed in internally referred patients (Ta-
ble 2, Figure 4B and 4C).
dIsCUssIoN
The main finding of the present analysis is a very low pro-
portion of patients with ≥70% INR values determined 
over a one-year period within the target range (INR 2.0-
3.5). Since the proportion of INR values determined over 
a period of time that are within target range corresponds 
well with the TTR determined by the linear interpolation 
method (12), data strongly suggest that warfarin anti-
coagulation in the observed patients requiring life-long 
thromboprophylaxis was by far poorer than recommend-
ed (2,3). A potential limitation of our study might be the 
definition of the target INR range. However, it is highly un-
likely that using the 2.0-3.0 range or different target rang-
es for prosthetic valve patients would have substantially 
changed the results since “off-target” INR values were al-
most exclusively <2.0. A further limitation might be that 
39.5% of the included patients were evaluated based on 
a relatively low number of INRs (three to seven), which 
might have reflected earlier treatment stages (we did not 
identify newly treated patients) when INRs generally show 
greater variability. However, comparably low proportions 
of adequately anticoagulated patients were consistently 
observed among patients with 8-12 INR values (37.8% of 
all patients) and those with >12 INRs (22.7% of all patients). 
Moreover, in patients with AF (67.3% of all patients) a high-
er number of determined INRs was not associated with a 
higher probability of adequate anticoagulation, while in 
patients with other conditions the values increased from 
extremely low (9.5%) to very low (25.2%). In line with ob-
servations by other authors (9), the proportion of patients 
who were adequately anticoagulated was higher in pa-
tients with AF than in patients with other conditions re-
quiring life-long thromboprohylaxis. This phenomenon 
has been attributed to more severe comorbidity and more 
extensive co-medication in patients with, eg, prosthetic 
valves, severe heart failure with atrial thrombi or very low 
ejection fraction, or those who suffered a stroke, which 
might make adequate anticoagulation more difficult 
to achieve (9). As expected, most of the “off-target” INRs 
were too low (INR<2.0) (across all levels of the number of 
determined INRs), a phenomenon that is commonly ob-
served (12). It suggests that the prescribers might be more 
afraid of bleeding complications than of thromboembo-
lic events, for which it is generally uncertain whether they 
will happen at all. Patients requiring life-long thrombopro-
phylaxis commonly have comorbid conditions that per se 
increase the risk of major bleeding (eg, fatal or life-threat-
ening by volume, intracerebral/intracranial), hence bleed-
ings occur even in non-anticoagulated patients, and ade-
quate anticoagulation does not increase this risk (1,17). On 
the other hand, inadequate anticoagulation, characterized 
by the predominance of low INR values, progressively in-
creases the risk of thromboembolic events, which is con-
siderably higher than the risk of major bleedings (1,12,17). 
While any form of thromboembolism can occur (either 
by an embolic mechanism or due to generally increased 
blood coagulability in these conditions), the most com-
mon is ischemic stroke (1-5). In a population-based study 
conducted in a Croatian county with a similarly sized and 
structured population as Zadar County (18), standardized 
incidence rate of first-ever ischemic stroke was consider-
ably higher than reported in surrounding and developed 
European countries. Among incident patients, 36.1% suf-
fered from AF and had additional risk factors for stroke 
that defined them as subjects who required anticoagula-
tion, yet only 3.0% of them actually received regular anti-
coagulant treatment before the index event (18). During 
one-year follow-up, mortality was 3-fold lower in patients 
who were anticoagulated than in those who were not 
(adjusted hazard ratio 0.27, 95% CI 0.12-0.61) (19). In a 
subsequent case-control study in the same popula-
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tion (19), the occurrence of first-ever ischemic stroke was 
strongly associated with known modifiable risk factors, eg, 
smoking, unhealthy diet, uncontrolled hypertension, un-
treated dyslipidemia, AF and, particularly, no anticoagula-
tion where it was indicated (19). In the light of these facts, 
the present data suggest that the high incidence of isch-
emic stroke and high case-fatality rates in stroke patients 
in Croatia are at least in part attributable to inadequate an-
ticoagulation in patients in whom it is indicated.
In conclusion, we observed a highly inadequate lev-
el of warfarin anticoagulation in patients requiring life-
long thromboprophylaxis in a Croatian county. Since the 
health care system organization is the same throughout 
the country, there is no reason to believe that the situ-
ation is relevantly different in any other part of Croatia. 
This is supported by the studies on the incidence and 
case-fatality rates of ischemic stroke in the Croatian pop-
ulation (18,19). Reports on the quality of anticoagulation 
with VKAs (and patient characteristics that may influence 
it) are extremely numerous and addressing them exceeds 
the scope of this work. The fact remains that even in the 
developed Western countries this quality may be less 
than desirable (20). Some of the cited studies (8-10) dem-
onstrate that high quality is achievable, but this mainly 
depends on the organizational aspects. Therefore, al-
though the present study provides no data that help ex-
plain the observations, it appears plausible that they are 
mainly due to the specifics of the health care system out-
lined in the Introduction. A recent survey on the quality 
of stroke prevention in atrial fibrillation in Croatia and the 
surrounding Balkan countries (facing similar health care 
organizational issues) (21) demonstrated that among 
1198 atrial fibrillation patients treated with VKAs over at 
least previous 6 months, %TTR for the previous 3 months 
could be determined in only 224 (18.7%) due to the lack 
of data, indicating a poor practice of required continuous 
and structured monitoring. At the individual patient level, 
ESC guidelines suggest either NOACs or VKAs as the treat-
ments of choice for patients with NVAF (the largest sub-
set of patients requiring life-long anticoagulation), and 
preference of NOACs in NVAF patients in whom adequate 
anticoagulation with VKAs cannot be achieved (1). Giv-
en that major health care system reorganizations are not 
likely to happen in Croatia, NOACs appear to be a gener-
ally preferable choice for these patients. However, just as 
in the case of the surrounding countries (22), the use of 
NOACs in NVAF patients in Croatia is relatively limited 
(even if medically justified) due to a strong influence 
of the reimbursement policy.
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